These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 1827575

  • 1. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer].
    Aikawa T, Yayoi E, Takatsuka Y, Maeura Y, Miyauchi K.
    Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
    Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
    [Abstract] [Full Text] [Related]

  • 4. [Study on CAF + medroxyprogesterone acetate (MPA) therapy for advanced or recurrent breast cancer--comparison between MPA 600 mg and 1,200 mg. Kyushu CAFT Therapy Study Group (Third Study)].
    Mitsuyama S, Ohno S, Koga T, Takayama T, Yamashita J, Ogawa M, Shirouzu K, Sugimachi K, Nomura Y, Ogawa N.
    Gan To Kagaku Ryoho; 1999 Nov; 26(13):2029-36. PubMed ID: 10584567
    [Abstract] [Full Text] [Related]

  • 5. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
    Sonoo H, Senoo T, Nishiki M, Morimoto T, Takashima S.
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
    [Abstract] [Full Text] [Related]

  • 6. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
    Yoshida M, Murai H, Miura S.
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [A comparative study between low-dose and high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer--in relation to dose, serum concentration and response. Osaka Breast Cancer Research Group].
    Furukawa J, Yayoi E, Takatsuka Y, Aikawa T, Maeura Y, Kobayashi T, Miyauchi K, Kotsuma Y.
    Gan To Kagaku Ryoho; 1997 May; 24(7):815-21. PubMed ID: 9170519
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
    Abe O, Tominaga T, Enomoto K, Abe R, Iino Y, Koyama H, Fujimoto M, Nomura Y, Tanaka T.
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2160-8. PubMed ID: 3717960
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A, Extra JM, Espié M, Cuvier C, Marty M.
    In Vivo; 1998 Jun; 12(5):559-62. PubMed ID: 9827368
    [Abstract] [Full Text] [Related]

  • 16. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
    Ueno K, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nakamura T, Ito Y, Imajo K, Ozeki H.
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
    Kiman K, Suzuki S, Satomi T, Sakonji M, Nihei M, Tanaka T, Kimijima I, Abe R.
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2445-52. PubMed ID: 7944490
    [Abstract] [Full Text] [Related]

  • 18. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
    Pannuti F, Longhi A, Martoni A, Piana E, Baroni M.
    Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
    [Abstract] [Full Text] [Related]

  • 19. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
    Noguchi S, Yamamoto H, Inaii H, Koyama H.
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
    [Abstract] [Full Text] [Related]

  • 20. Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer.
    Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, Ohwada S, Morishita Y.
    Anticancer Res; 1996 Nov; 16(4A):2069-72. PubMed ID: 8712744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.